Two double-blinded, randomized, comparative trials of 4 Human Immunodeficiency Virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS clinical trials groups 209 and 214

AIDS Clinical Trials Group 209 and 214 Study Teams

Research output: Contribution to journalArticle

Abstract

The potential role of human immunodeficiency virus type 1 (HIV-1)-specific immune responses in controlling viral replication in vivo has stimulated interest in enhancing virus-specific immunity by vaccinating infected individuals with HIV-1 or its components. These studies were undertaken to define patient populations most likely to respond to vaccination, with the induction of novel HIV-1-specific cellular immune responses, and to compare the safety and immunogenicity of several candidate recombinant HIV-1 envelope vaccines and adjuvants. New lymphoproliferative responses (LPRs) developed in <30% of vaccine recipients. LPRs were elicited primarily in study participants with a CD4 cell count >350 cells/mm3 and were usually strain restricted. Responders tended to be more likely than nonresponders to have an undetectable level of HIV-1 RNA at baseline (P =.067). Induction of new cellular immune responses by HIV-1 envelope vaccines is a function of the immunologic stage of disease and baseline plasma HIV-1 RNA level and exhibits considerable vaccine strain specificity.

Original languageEnglish (US)
Pages (from-to)1357-1364
Number of pages8
JournalJournal of Infectious Diseases
Volume182
Issue number5
DOIs
StatePublished - Jan 1 2000

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this